Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 10/24/2025 at 22:15, 6 months 16 days ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress

Gastrointestinal Distress Jaguar Health RSUs New Employees Prescription Medicines
BRIEF

published on 10/06/2025 at 15:05, 7 months 4 days ago

Jaguar Health fait progresser le développement du Crofelemer pour le traitement de la MVID lors d'une réunion de la FDA

Crofelemer Jaguar Health MVID Réunion De La FDA Procès Aux Émirats Arabes Unis
BRIEF

published on 10/06/2025 at 15:05, 7 months 4 days ago

Jaguar Health Advances Development with FDA Meeting on Crofelemer for MVID Treatment

Crofelemer Jaguar Health MVID FDA Meeting UAE Trial
PRESS RELEASE

published on 10/06/2025 at 15:00, 7 months 4 days ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement

FDA Napo Pharmaceuticals Clinical Trial Pediatric Patients MVID
BRIEF

published on 09/30/2025 at 15:05, 7 months 10 days ago

Jaguar Health Provides Crofelemer for Pediatric Intestinal Failure Treatment

Crofelemer Microvillus Inclusion Disease Jaguar Health Pediatric Treatment FDA Programs
BRIEF

published on 09/30/2025 at 15:05, 7 months 10 days ago

Jaguar Health fournit Crofelemer pour le traitement de l'insuffisance intestinale pédiatrique

Crofelemer Jaguar Health Maladie D'inclusion Microvillositaire Traitement Pédiatrique Programmes De La FDA
PRESS RELEASE

published on 09/30/2025 at 15:00, 7 months 10 days ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Jaguar Health announces expanded access programs for pediatric patients with microvillus inclusion disease using crofelemer powder. Positive results from initial trials presented

Microvillus Inclusion Disease Jaguar Health Pediatric Patients Crofelemer Powder Expanded Access Programs
BRIEF

published on 09/26/2025 at 12:22, 7 months 14 days ago

Jaguar Health Inc's Stock Recommendation Reiterated as BUY

Funding Jaguar Health Stock Recommendation Rare Diseases First Berlin
BRIEF

published on 09/26/2025 at 12:22, 7 months 14 days ago

Jaguar Health Inc. réitère sa recommandation d'achat sur ses actions

Financement Jaguar Health Maladies Rares Premier Berlin Recommandation D'actions
PRESS RELEASE

published on 09/26/2025 at 12:17, 7 months 14 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates recommendation for Jaguar Health Inc to BUY with a target price of USD 35. Company reports H1/25 results in line with estimates, focuses on securing funding for promising pipeline

Jaguar Health Inc Funding First Berlin Equity Research Buy Recommendation Research Update

Accesswire

Published on 05/09/2026 at 01:55, 1 day 15 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 15 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 15 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 17 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 18 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 1 hour 11 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 3 hours 16 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 5 hours 31 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 22 hours 11 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 20 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 2 days 22 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 22 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 22 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 22 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 22 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE